PT  - JOURNAL ARTICLE
AU  - Shurong Hou
AU  - Tania V. Slivas
AU  - Florian Leidner
AU  - Ellen A. Nalivaika
AU  - Hiroshi Matsuo
AU  - Nese Kurt Yilmaz
AU  - Celia A. Schiffer
TI  - Structural analysis of the active site and DNA binding of human cytidine deaminase APOBEC3B
AID  - 10.1101/304170
DP  - 2018 Jan 01
TA  - bioRxiv
PG  - 304170
4099  - http://biorxiv.org/content/early/2018/04/18/304170.short
4100  - http://biorxiv.org/content/early/2018/04/18/304170.full
AB  - APOBEC3s proteins (A3s), a family of human cytidine deaminases, protect the host cell from endogenous retro-elements and exogenous viral infections by introducing hypermutations. However, the ability to mutate genomic DNA makes A3s a potential cancer source. Of the 7 human A3s, A3B has been implicated as an endogenous cause for multiple cancers. Despite overall similarity, A3s have distinct deamination activity with A3B among the least catalytically active. Over the past few years, several structures of apo as well as DNA-bound A3 proteins have been determined. These structures revealed the molecular determinants of nucleotide specificity and the importance of the loops around the active site in DNA binding. However, for A3B, the structural basis for regulation of deamination activity and the role of active site loops in coordinating DNA had remained unknown. In this study, using a combination of advanced molecular modelling followed by experimental mutational analysis and dynamics simulations, we investigated molecular mechanism of A3B regulating activity and DNA binding. We identified a unique auto-inhibited conformation of A3B that restricts access and binding of DNA to the active site, mainly due to the extra PLV residues in loop 1. We modelled DNA binding to fully native A3B and found that Arg211 in the arginine patch of loop1 is the gatekeeper while Arg212 stabilizes the bound DNA. This model also identified the critical residues for substrate specificity, especially at the -1 position. Our results reveal the structural basis for relatively lower catalytic activity of A3B and provide opportunities for rational design of inhibitors that specifically target A3B to benefit cancer therapeutics.